Recent fluctuations in the stock market have drawn investors’ attention to shares of Novo Nordisk A/S $NVO, which dropped by 9.8% to 380 Danish krone. This decline comes amid concerns regarding new weight loss pills introduced by competitor Eli Lilly & Co. $LLY. Such news raises questions about the future of bestselling drugs like Ozempic and their ability to maintain market positions in a rapidly evolving environment.